Warning letter
Recsei Laboratories, LLC: warning letter of Jan 15, 2014
FDA warning letter 411718 · Los Angeles District Office
Key facts
| Reference number | 411718 |
|---|---|
| Company | Recsei Laboratories, LLC |
| Subject | Unapproved and Misbranded New Drugs |
| Issue date | Jan 15, 2014 |
| Posted date | Feb 4, 2014 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 211.84(d)(2), 201.115, 211.87, 211.137, 211.67(b), 211.166(a) |
| Inspection city | Goleta |
| Inspection ZIP | 93117 |
| Inspection start date | Jul 1, 2013 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- VAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: